BioAlliance's 3rd-qtr revenue up 240%
Paris, France-based BioAlliance Pharma SA says that its consolidated revenues for the third quarter of 2006 were 102,000 euros ($134.4 million), a 240% increase on its turnover in the comparable period last year. The company said that the bulk of its sales were in relation to services it supplied to Eurofins-VIRalliance (EVI).
Loramyc approved in France
BioAlliance also announced that the French authorities had granted its product Loramyc (miconzole Lauriad), a bioadhesive antifungal treatment, approval for use in oropharyngeal candidiasis in immunosuppressed patients. The product is also in a pivotal Phase III trial in the USA for the same indication.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze